Emyria has achieved a major milestone, as dosing has officially commenced in our Phase 3 Clinical Trial of Ultra-Pure CBD medication EMD-RX5.

The Phase 3 clinical trial is a pivotal step towards our goal of TGA registration of EMD-RX5 as a solid capsule medicine, aimed at treating mild anxiety and stress, that is available over the counter.

To read more about Emyria’s unique approach and the competitive advantages of Ultra-Pure CBD and our Real-World Data, visit our Investor Hub to read the full statement: ASX Announcements | Emyria Investor Hub